On March 13, 2025, a delegation led by Mr. Dmitry Polstyanov and Mr. Aleksandr Didenko from Russia’s Skopinpharm Company, along with Mr. DaeYoon Jin from South Korea’s MDICOBUTIS Company, paid a visit to our company. The delegation was warmly received by Mr. Xu Songshan, Chairman of the Board, Ms. Nie Liya, Executive Vice President, and Mr. Han Chengquan, Vice President. During the visit, the delegation engaged in an in-depth exchange on matters related to future international cooperation. At the symposium, Han Chengquan, Vice President of the company, provided a detailed introduction to NORTHLAND Group’s development history, core technologies, and product pipeline. Nie Liya, Executive Vice President and General Manager of the subsidiary Huienland, introduced Huienland’s basic information as well as its ophthalmic technology platform and products. Mr. Dmitry Polstyanov, Commercial Director of Skopinpharm, presented an overview of the company, the current state and demand of the Russian pharmaceutical market, and shared insights into key aspects of Russian GMP standards, drug registration and review regulations, market access, and supply chain models. Both sides engaged in an in-depth discussion on comprehensive cooperation in areas such as drug R&D, technology, manufacturing, and sales, and made preliminary arrangements for subsequent specific tasks. Chairman Xu Songshan accompanied the delegation on a tour of Huienland’s eye-drop production workshop, where he provided a detailed introduction to the dropper solution production line and the entire process of production and quality control. The Russian representative highly praised the professional strengths and competitiveness of NORTHLAND’s NL003 and Huienland ophthalmic products, and expressed great recognition for the company’s quality management system, production processes and technological level, rigorous work attitude, and high-quality assurance measures. He stated that Russia’s demand for high-quality pharmaceuticals continues to grow, and he hopes to accelerate cooperation as soon as possible to provide even better products to the Russian pharmaceutical market and its patients.
Mr. Xu Songshan, Chairman of the company, stated that NORTHLAND, as a Chinese innovative pharmaceutical company, has always been committed to new drug research and development. Expanding into international markets is one of the company’s key strategic priorities, and the cooperation between the two sides holds great promise. He expressed hope that the collaboration process could be accelerated so that NORTHLAND’s products could be introduced to Russia at an early date, achieving mutual benefit and win-win outcomes for both parties. The company also actively supports China’s “Belt and Road” initiative and is contributing to the economic cooperation and development of countries and regions along the Belt and Road.
        About Skopinpharm Company
Skopinpharm is one of the companies under the Russian PHARMIMEX Group. The group was founded in 1936 and was a large state-owned pharmaceutical enterprise during the Soviet era. It acquired Skopinpharm in 2013. Skopinpharm boasts pharmaceutical production lines that meet international GMP standards and primarily manufactures solid dosage forms, blood products, vaccines, monoclonal antibodies, and other products. The PHARMIMEX Group has an extensive pharmaceutical distribution network throughout Russia and is committed to introducing and promoting internationally advanced pharmaceutical products. It collaborates with numerous multinational corporations, including Johnson & Johnson, Novartis, and Baxter.